GBP Health / Biotech News 04-26-2010:
Since August, 2005, this news digest has been a complimentary service of GBP Capital, a private equity firm investing in early to mid-stage life science companies. See www.gbpcap.com. The digest is published two to four days a week. If you have colleagues who would be interested in receiving this digest by email, they can be added to the list at: http://www.gbpcap.com/. Also, the complete history of the entire content of all news articles in our digests since August, 2005 is searchable with Google's enterprise search engine at the same site.
EurekAlert - Biology:
Public Release: 26-Apr-2010
Grapes reduce risk factors for heart disease and diabetes, U-M animal study shows
Scientists at the University of Michigan Health System are teasing out clues to the effect of grapes in reducing risk factors related to cardiovascular disease and metabolic syndrome. The effect is thought to be due to phytochemicals -- naturally occurring antioxidants -- that grapes contain.
Contact: Tara Hasouris
tarahaso@umich.edu
734-764-2220
University of Michigan Health System
Public Release: 25-Apr-2010
Experimental Biology 2010
Lengthening time a drug remains bound to a target may lead to improving diagnostics, therapy
Studies indicate that modifications that enhance the time a drug remains bound to its target, or residence time, may lead to better diagnostic and therapeutic agents.
Contact: Nicole Kresge
nkresge@asbmb.org
202-316-5447
Federation of American Societies for Experimental Biology
Public Release: 25-Apr-2010
Nature
Gene silencing may be responsible for induced pluripotent stem cells' limitations
Scientists may be one step closer to being able to generate any type of cells and tissues from a patient's own cells. Investigators from the Massachusetts General Hospital Center for Regenerative Medicine and the Harvard Stem Cell Institute have found that an important cluster of genes is inactivated in those induced pluripotent stem cells lacking the full development potential of embryonic stem cells.
Howard Hughes Medical Institute, National Institute of Health, Schering Foundation, Jane Coffin Childs Memorial Fund, Sanofi-Aventis
Contact: Sue McGreevey
smcgreevey@partners.org
617-724-2764
Massachusetts General Hospital
Source - Science Daily :
Please note : Due to the format restrictions of Science Daily articles, you must click on the URL (web address) below the article summary , rather than the article title.
Molecular Structure of Key Fluorescent Proteins Revealed
April 26, 2010 — Scientists have determined the crystal structures of two key fluorescent proteins -- one blue, one red -- used to "light up" molecules in cells. The researchers now have the first roadmap for ...
http://www.sciencedaily.com/releases/2010/04/100422141159.htm
Prostate Cancer: Risk Increases With the Number of Affected Family Members
April 25, 2010 — The risk of getting prostate cancer increases with the number of directly related family members who are affected by the disease. Scientists in Germany have now calculated the age-specific individual ...
http://www.sciencedaily.com/releases/2010/04/100423113724.htm
Complete Revascularization Improves Outcomes for Coronary Artery Disease Patients
April 25, 2010 — A three-year, retrospective study by cardiologists determined that 28.8 percent of patients with significant coronary artery disease who did not undergo complete revascularization had a higher ...
http://www.sciencedaily.com/releases/2010/04/100423113726.htm
Protein Plays a Critical Role in the Development of Aggressive Breast Cancer
April 24, 2010 — Researchers have identified a potentially significant molecular player in the development of aggressive breast cancer. The team's findings show that a protein called NEDD9 is critical in the ...
http://www.sciencedaily.com/releases/2010/04/100420101229.htm
Cloud Technology to Combat Cancer
April 23, 2010 — Cloud services provided over grid technology are helping to treat cancer patients, thanks to an enormous effort by European researchers working closely with ...
http://www.sciencedaily.com/releases/2010/04/100420161220.htm
Substance in Breast Milk Kills Cancer Cells, Study Suggests
April 23, 2010 — A substance found in breast milk can kill cancer cells, reveal a new ...
http://www.sciencedaily.com/releases/2010/04/100419132403.htm
Potential for New Cancer Detection and Therapy Method Described
April 23, 2010 — Scientists have described a potentially new early cancer detection and treatment method using nanoparticles. A new paper illustrates how engineered gold nanoparticles tied to a cancer-specific ...
http://www.sciencedaily.com/releases/2010/04/100422170151.htm
April 23, 2010 — The standard practice of cooling and then rewarming a patient to prevent organ damage during cardiac bypass surgery may impair the body's mechanism that controls blood flow to the brain, potentially ...
http://www.sciencedaily.com/releases/2010/04/100422141154.htm
Source - Health Day:
Health Highlights: April 22, 2010
- Spending Will Increase Under New Health Law: Report
- Croatian Girl Speaks Only German After Waking From Coma
- Vatican Funds Adult Stem Cell Research
- Doctors Report World's First Full-Face Transplant
- Major Study Will Examine Cell Phone Health Risks
Smoking May Be in Your Genes
Findings may someday help in development of prevention efforts, experts say.
FDA Targets Safety Problems With Infusion Drug Pumps
More than 56,000 reports of problems, 500 deaths have prompted agency to act
Cancer Drug Seems to Work by Activating Virus
Finding could apply to many Epstein-Barr-related cancers, researchers say
Clinical Trials Update: Apr. 23, 2010
- Chronic Obstructive Pulmonary Disease (COPD)
- Hepatitis B Vaccine
- Gout
Source - Yahoo Biotech News:
OSI Pharmaceuticals Announces That "RADIANT", an International Phase III Tarceva Adjuvant Trial in Non-Small Cell Lung Cancer, Completes Enrollment- Business Wire - 2 hours, 52 minutes ago
MELVILLE, N.Y.----OSI Pharmaceuticals, Inc. announced today that it has completed enrollment in the RADIANT study, a Phase III clinical trial testing Tarceva® as an adjuvant therapy in patients with Stage IB-IIIA non-small cell lung cancer who have undergone surgery and have EGFR-positive tumors.
Nycomed and Merck & Co., Inc., Announce Commercialization Agreements For Daxas � in Europe and Canada- Business Wire - Mon 2:00 am ET
ZURICH & WHITEHOUSE STATION, N.J.----Nycomed and Merck & Co., Inc. today announced that they have entered into a co-promotion agreement for Canada and certain European countries for the commercialization of Daxas® , an investigational once-daily tablet for patients with chronic obstructive pulmonary disease .
Source - Google Health News:
Modified Virus Wipes Cancer Cells
Laboratory Equipment
They were also able to add these retargeting proteins to an existing gene therapy virus so that it recognised and attacked these bladder cancer cells, ...
Gene therapy rises from the dead
FierceBiotech
Gene therapy--the idea of replacing a patient's defective genes with healthy ones--was hyped in the 1990s as the next big leap forward in drug development. ...
Current concepts and recent research findings on gene therapy for inner ear ...
News-Medical.net
Gene therapy holds great potential for the treatment not only of genetic disorders, but also of many acquired diseases. This is as true for the inner ear as ...
Gene Expression Therapy With Resveratrol Helps Humans and Equines
Suite101.com
Gene therapy is the newest hope to control metabolic syndrome and prevent inflammatory conditions in equines. Genes build muscles and function capabilities ...
Source - Medical News Today :
World's First Full Face Transplant A Success Say Spanish Doctors
Spanish doctors who carried out a full face transplant on a man who injured himself in a shooting accident five years ago that left him unable to breathe or swallow, said the operation, the first of its kind in the world, has been a success. The 30-doctor team at Vall d'Hebron University Hospital in Barcelona operated for over 20 hours to transplant a completely new face from the donor to the recipient, a young farmer who accidentally shot himself in the face in 2005.
http://www.medicalnewstoday.com/articles/186612.php
Need For Strategies To Address Overdiagnosis In Cancer
Many cancers detected by screening tests are not destined to cause symptoms or death and therefore represent a phenomenon known as overdiagnosis. And because overdiagnosis leads to unnecessary treatment and other harms, it is important to develop clinical and research strategies to quantify, recognize, and manage it, according to a review published online in the Journal of the National Cancer Institute. H. Gilbert Welch, M.D. and William Black, M.D., of the Dept. of Veterans Affairs Medical Center, White River Junction, Vt. and the Dartmouth-Hitchcock Medical Center used data from large randomized screening trials to estimate the extent of overdiagnosis. They found that about 25% of breast cancers detected on mammograms and about 60% of prostate cancers detected with prostate-specific antigen (PSA) tests could represent overdiagnosis. In a lung cancer screening trial of chest x-rays and sputum tests, they estimate that 50% of the cancers detected represented overdiagnosis. They argue that this estimate will only increase with spiral CT scanning, which, in one observational study, found almost as many lung cancers in non-smokers as smokers.
http://www.medicalnewstoday.com/articles/186486.php
SuperSonic Imagine Unveils Results Of Largest Breast Ultrasound Clinical Trial Ever Undertaken
SuperSonic Imagine, the innovative medical imaging company based in Aix-en-Provence, France has unveiled some of the results of the largest clinical breast study ever undertaken in ultrasound imaging. The worldwide multicenter study, involving top clinicians in the breast radiology community, is assessing the clinical benefits of ShearWave™ Elastography in the ultrasonic evaluation of breast lesions. The study has two objectives: The first is to demonstrate that images obtained using ShearWave™ Elastography are reproducible. The second is to compare ultrasound alone versus the combination of ultrasound and ShearWave™ Elastography for breast lesion diagnosis. The goal of the latter is to improve lesion classification in categories BI-RADS ® 3 and BI-RADS ® 4(i) in order to better direct patients towards clinical follow-up or biopsy.
http://www.medicalnewstoday.com/articles/186545.php
Source - MIT's Technology Review:
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.